Lenzilumab

Drug Profile

Lenzilumab

Alternative Names: KB-003

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator KaloBios Pharmaceuticals
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic myelomonocytic leukaemia
  • Research Solid tumours
  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 29 Nov 2016 KaloBios plans a phase I trial in Juvenile myelomonocytic leukaemia
  • 19 Nov 2015 KaloBios resumes phase-I/II clinical trials in Chronic myelomonocytic leukaemia (Second line therapy or greater) in USA (IV)
  • 13 Nov 2015 Suspended - Phase-I/II for Chronic myelomonocytic leukaemia (Second line therapy or greater) in USA (IV) (NCT02546284)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top